Business Context and Reporting Period
Company: Rockwell Medical, Inc. (RMTI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Rockwell Medical develops, manufactures, and distributes hemodialysis concentrates (liquid and dry acid/bicarbonate) for dialysis providers in the U.S. and internationally. The company operates manufacturing facilities in Michigan and Texas and concluded operations at its South Carolina facility in Q3 2025 to streamline costs. It serves 294 customers, including all five leading U.S. dialysis providers.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Sales | $69.3 million | $101.5 million |
| Gross Profit | $11.7 million | $17.5 million |
| Gross Margin | 16.9% | 17.2% |
| Operating Income (Loss) | $(4.7) million | $0.6 million |
| Net Loss | $(5.3) million | $(0.5) million |
| Cash & Equivalents | $10.7 million | $15.7 million |
| Total Investments (Available-for-Sale) | $14.3 million | $5.9 million |
| Working Capital | $28.6 million | $22.9 million |
| Long-Term Debt (Net) | $8.8 million | $8.5 million |
| Accumulated Deficit | $(403.0) million | $(397.7) million |
Liquidity: The company reported net cash used in operating activities of $0.7 million in 2025. Management believes current resources are sufficient to meet operating requirements for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 31.8% to $69.3 million, primarily driven by a $34.6 million reduction in sales to DaVita, Inc. DaVita's share of total net sales dropped from 45% in 2024 to 16% in 2025.
- Operational Restructuring: The company ceased manufacturing at its Greer, South Carolina facility in Q3 2025 to reduce overhead. This resulted in $1.0 million in severance and closure costs recorded in Cost of Sales.
- Profitability: The company shifted from an operating income of $0.6 million in 2024 to an operating loss of $4.7 million in 2025. Gross profit declined $5.8 million due to lower volumes and increased manufacturing/severance costs, partially offset by price adjustments.
- Customer Diversification: While DaVita sales declined, the company added 30 new customers in the western U.S. and signed a multi-year agreement with Innovative Renal Care. International sales increased to 12% of total revenue (from 9% in 2024).
Guidance, Outlook, and Risks
Management Commentary: Management is focused on right-sizing operations, securing price increases, and acquiring new customers to offset the loss of DaVita volume. The company extended its agreement with DaVita through December 31, 2026, with increased pricing.
Outlook: The company expects to fund operations for the next 12 months using existing cash, investments, and an At-The-Market (ATM) equity facility with $13.1 million remaining capacity. Long-term success depends on achieving sustained profitability and executing growth strategies.
Key Risks & Contingencies:
- Customer Concentration: Despite diversification efforts, the loss of significant customers remains a material risk.
- Debt Covenants: The company has a $8.8 million term loan with Innovatus Life Sciences. It must maintain minimum liquidity and revenue covenants. Failure to comply could trigger an event of default and immediate repayment.
- Regulatory & Supply Chain: The business is subject to FDA regulations and risks related to raw material costs, labor shortages, and fuel prices.
- Going Concern: While management asserts sufficiency of funds for 12 months, the company has a cumulative deficit of $403 million and relies on future capital raises or operational improvements to sustain long-term viability.
Investor Verification Checklist
- DaVita Contract Status: Verify the specific terms and volume commitments of the amended DaVita agreement extending to 2026 to assess revenue stability.
- Debt Covenant Compliance: Monitor quarterly revenue and liquidity metrics against the Innovatus loan covenants (80-85% of projected revenue and minimum liquidity thresholds).
- ATM Facility Usage: Track the utilization of the remaining $13.1 million ATM facility and the dilution impact on existing shareholders.
- Cost Structure: Confirm that the closure of the South Carolina facility has resulted in the projected reduction in fixed operating costs.
- Chargeback Accruals: Review the $1.0 million chargeback accrual identified as a critical audit matter, as it involves significant estimation regarding distributor inventory sell-through.